Release primary care capacity with home testing
Reduce chronic disease management backlogs and improve kidney health outcomes with digital screening
Funded Programmes Available
Healthy.io in partnership with NHSx, the Accelerated Access Collaborative and the National Institute for Health Research, are offering substantial funding opportunities to release primary care capacity by allowing people at increased risk of chronic kidney disease (CKD) to complete their annual urine test at home.
Staff in participating GP practices will no longer have to process urine samples and vulnerable patients at increased risk of contracting COVID don’t have to visit the surgery to take their test.
This nationally significant programme, announced by Health and Social Care Secretary Matt Hancock, uses tried and tested technology to improve outcomes in essential annual kidney health testing for people with diabetes and hypertension, closing gaps around poor compliance with national recommendations on testing which is known to be beneficial in the early detection and prevention of CKD.
Funding packages of 50% to 100% are helping this COVID safe chronic kidney disease early detection service catalyse the national restoration and recovery process by providing GPs with an easily deliverable solution to clear chronic disease management backlogs remotely.
We send ACR test kits directly to eligible patients' homes with their prior consent
Patients self-test using our test kit and smartphone app, which guides them easily
Results are analysed and uploaded to SystmOne or EMIS workflows in real time
found the test 'easy' or 'very
easy' to use
preferred testing at home
vs. testing at the clinic
would recommend this service
to a friend
Clinical-Grade Testing from Home
The CKD early detection service increases adherence to annual urinary albumin to creatinine ratio (ACR) testing, which is known to be beneficial in the early detection and prevention of CKD, is recommended by NICE, and monitored by the National Diabetes Audit.
The test is built around the existing ACR point of care dipstick. It measures semi quantitative analysis of microalbumin (10 – 150 mg/L), creatinine (10 – 300mg/dL) and albumin to creatinine ratio (mg/g).
Results are expressed as ACR normal (<30mg/g), ACR abnormal (30-300mg/g) or ACR high abnormal (>300mg/g).
The product is CE marked, GDPR compliant, and follows industry standards for privacy and safety.
Barking and Dagenham CCG
Call for Expressions of Interest
We are seeking immediate expressions of interest from GP Practices, PCNs, CCGs, STPs, and other forward-thinking partners interested in empowering their patients and improving care through an evidence-based, time-saving, and patient-focused digital technology.
The availability of funding varies regionally ranging from 50% to 100% subsidies. Please express your interest before 5 pm on 11th June. Once submitted, we will be in touch to discuss the next steps towards releasing these benefits for your patient population at scale.
Please contact [email protected] with any questions.
- Judith Shore, Michelle Green, Andrew Hardy & Deborah Livesey (2019): The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2019.1650024